Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

RNA Stock Forecast


Avidity Biosciences stock forecast is as follows: an average price target of $54.50 (represents a 21.60% upside from RNA’s last price of $44.82) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

RNA Price Target


The average price target for Avidity Biosciences (RNA) is $54.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $59.00 to $50.00. This represents a potential 21.60% upside from RNA's last price of $44.82.

RNA Analyst Ratings


Buy

According to 8 Wall Street analysts, Avidity Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RNA stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Avidity Biosciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024Corinne JohnsonGoldman Sachs$59.00$43.5035.63%31.64%
Jun 12, 2024Yanan ZhuWells Fargo$50.00$28.9272.89%11.56%
Row per page
Go to

The latest Avidity Biosciences stock forecast, released on Sep 24, 2024 by Corinne Johnson from Goldman Sachs, set a price target of $59.00, which represents a 35.63% increase from the stock price at the time of the forecast ($43.50), and a 31.64% increase from RNA last price ($44.82).

Avidity Biosciences Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$59.00$54.50
Last Closing Price$44.82$44.82$44.82
Upside/Downside-100.00%31.64%21.60%

In the current month, the average price target of Avidity Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avidity Biosciences's last price of $44.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024Goldman SachsBuyBuyHold
Oct 21, 2024NeedhamBuyBuyHold
Oct 21, 2024Goldman SachsUnderperformUnderperformHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 03, 2024Goldman SachsBuyBuyHold
Sep 24, 2024Goldman Sachs-BuyInitialise
Sep 16, 2024Evercore PartnersUnderperformUnderperformHold
Sep 16, 2024NeedhamBuyBuyHold
Aug 28, 2024Barclays-OverweightInitialise
Aug 12, 2024NeedhamBuyBuyHold
Row per page
Go to

Avidity Biosciences's last stock rating was published by Goldman Sachs on Oct 30, 2024. The company gave RNA a "Buy" rating, the same as its previous rate.

Avidity Biosciences Financial Forecast


Avidity Biosciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue-------------$2.82M$2.32M$2.23M$2.77M$2.48M$2.18M$1.79M$1.85M$2.16M$2.61M$2.70M$2.14M$1.75M$1.54M
Avg Forecast$4.33M$4.02M$3.73M$3.46M$4.03M$4.03M$3.53M$3.53M$2.40M$4.07M$2.63M$2.57M$12.21M$2.21M$2.14M$2.04M$2.16M$2.13M$2.11M$1.90M$2.17M$2.13M$1.94M$1.00M$838.75K$575.00K$700.00K
High Forecast$4.33M$4.02M$3.73M$3.46M$4.03M$4.03M$3.53M$3.53M$2.40M$4.07M$2.63M$2.57M$23.86M$2.21M$2.14M$2.04M$2.16M$2.13M$2.11M$1.90M$2.17M$2.13M$1.94M$1.00M$838.75K$575.00K$700.00K
Low Forecast$4.33M$4.02M$3.73M$3.46M$4.03M$4.03M$3.53M$3.53M$2.40M$4.07M$2.63M$2.57M$570.98K$2.21M$2.14M$2.04M$2.16M$2.13M$2.11M$1.90M$2.17M$2.13M$1.94M$1.00M$838.75K$575.00K$700.00K
# Analysts222211112422422211112222222
Surprise %-------------1.27%1.08%1.09%1.28%1.17%1.03%0.94%0.85%1.02%1.35%2.70%2.55%3.04%2.20%

Avidity Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $12.21M, with a low forecast of $570.98K, and a high forecast of $23.86M. RNA's average Quarter revenue forecast represents a 333.33% increase compared to the company's last Quarter revenue of $2.82M (Sep 23).

Avidity Biosciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211112422422211112222222
EBITDA-------------$-58.06M$-52.63M$-57.60M$-53.23M$-44.56M$-45.98M$-34.15M$-38.33M$-29.10M$-26.21M$-23.74M$-16.16M$-11.34M$-10.35M
Avg Forecast$-4.33M$-4.02M$-3.73M$-3.46M$-4.03M$-4.03M$-3.53M$-3.53M$-2.40M$-4.07M$-2.63M$-2.57M$-12.21M$-2.21M$-2.14M$-2.04M$-2.16M$-2.13M$-2.11M$-37.46M$-2.17M$-2.13M$-1.94M$-20.35M$-838.75K$-575.00K$-29.11M
High Forecast$-4.33M$-4.02M$-3.73M$-3.46M$-4.03M$-4.03M$-3.53M$-3.53M$-2.40M$-4.07M$-2.63M$-2.57M$-570.98K$-2.21M$-2.14M$-2.04M$-2.16M$-2.13M$-2.11M$-29.97M$-2.17M$-2.13M$-1.94M$-16.28M$-838.75K$-575.00K$-23.29M
Low Forecast$-4.33M$-4.02M$-3.73M$-3.46M$-4.03M$-4.03M$-3.53M$-3.53M$-2.40M$-4.07M$-2.63M$-2.57M$-23.86M$-2.21M$-2.14M$-2.04M$-2.16M$-2.13M$-2.11M$-44.95M$-2.17M$-2.13M$-1.94M$-24.41M$-838.75K$-575.00K$-34.93M
Surprise %-------------26.23%24.54%28.17%24.64%20.97%21.76%0.91%17.62%13.69%13.53%1.17%19.27%19.72%0.36%

undefined analysts predict RNA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Avidity Biosciences's previous annual EBITDA (undefined) of $NaN.

Avidity Biosciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211112422422211112222222
Net Income-------------$-52.36M$-47.02M$-47.19M$-47.72M$-42.27M$-44.47M$-34.01M$-38.53M$-29.27M$-26.34M$-23.83M$-16.26M$-11.41M$-10.74M
Avg Forecast$-117.10M$-117.14M$-109.49M$-109.53M$-84.47M$-83.67M$-78.70M$-78.06M$-81.02M$-76.07M$-80.86M$-85.13M$-70.50M$-80.91M$-84.80M$-89.65M$-95.08M$-99.79M$-82.26M$-38.09M$-74.58M$-72.39M$-76.19M$-20.44M$-36.62M$-39.03M$-29.69M
High Forecast$-117.10M$-117.14M$-109.49M$-109.53M$-84.47M$-83.67M$-78.70M$-78.06M$-81.02M$-53.92M$-80.86M$-85.13M$9.14M$-80.91M$-84.80M$-89.65M$-95.08M$-99.79M$-82.26M$-30.47M$-74.58M$-72.39M$-76.19M$-16.35M$-36.62M$-39.03M$-23.75M
Low Forecast$-117.10M$-117.14M$-109.49M$-109.53M$-84.47M$-83.67M$-78.70M$-78.06M$-81.02M$-90.51M$-80.86M$-85.13M$-114.89M$-80.91M$-84.80M$-89.65M$-95.08M$-99.79M$-82.26M$-45.70M$-74.58M$-72.39M$-76.19M$-24.53M$-36.62M$-39.03M$-35.63M
Surprise %-------------0.65%0.55%0.53%0.50%0.42%0.54%0.89%0.52%0.40%0.35%1.17%0.44%0.29%0.36%

Avidity Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RNA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Avidity Biosciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211112422422211112222222
SG&A-------------$13.73M$12.28M$12.06M$10.38M$10.09M$8.69M$8.57M$7.43M$6.61M$6.27M$5.88M$4.82M$3.76M$2.92M
Avg Forecast$14.32M$13.28M$12.32M$11.43M$13.33M$13.33M$11.69M$11.69M$7.95M$13.46M$8.68M$8.50M$40.39M$7.32M$7.09M$6.76M$7.14M$7.03M$6.99M$6.28M$7.19M$7.03M$6.41M$3.31M$2.77M$1.90M$2.32M
High Forecast$14.32M$13.28M$12.32M$11.43M$13.33M$13.33M$11.69M$11.69M$7.95M$13.46M$8.68M$8.50M$78.90M$7.32M$7.09M$6.76M$7.14M$7.03M$6.99M$6.28M$7.19M$7.03M$6.41M$3.31M$2.77M$1.90M$2.32M
Low Forecast$14.32M$13.28M$12.32M$11.43M$13.33M$13.33M$11.69M$11.69M$7.95M$13.46M$8.68M$8.50M$1.89M$7.32M$7.09M$6.76M$7.14M$7.03M$6.99M$6.28M$7.19M$7.03M$6.41M$3.31M$2.77M$1.90M$2.32M
Surprise %-------------1.88%1.73%1.78%1.45%1.44%1.24%1.36%1.03%0.94%0.98%1.78%1.74%1.98%1.26%

Avidity Biosciences's average Quarter SG&A projection for Dec 23 is $40.39M, based on 4 Wall Street analysts, with a range of $1.89M to $78.90M. The forecast indicates a 194.16% rise compared to RNA last annual SG&A of $13.73M (Sep 23).

Avidity Biosciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211112422422211112222222
EPS-------------$-0.71$-0.66$-0.67$-0.83$-0.80$-0.89$-0.70$-1.63$-0.68$-0.70$-0.64$-0.43$-0.30$-1.25
Avg Forecast$-1.10$-1.10$-1.02$-1.02$-0.79$-0.78$-0.74$-0.73$-0.76$-0.71$-0.76$-0.80$-0.66$-0.76$-0.79$-0.84$-0.89$-0.93$-0.77$-0.80$-0.70$-0.68$-0.71$-0.56$-0.34$-0.36$-0.36
High Forecast$-1.10$-1.10$-1.02$-1.02$-0.79$-0.78$-0.74$-0.73$-0.76$-0.50$-0.76$-0.80$0.09$-0.76$-0.79$-0.84$-0.89$-0.93$-0.77$-0.80$-0.70$-0.68$-0.71$-0.56$-0.34$-0.36$-0.36
Low Forecast$-1.10$-1.10$-1.02$-1.02$-0.79$-0.78$-0.74$-0.73$-0.76$-0.85$-0.76$-0.80$-1.07$-0.76$-0.79$-0.84$-0.89$-0.93$-0.77$-0.80$-0.70$-0.68$-0.71$-0.56$-0.34$-0.36$-0.36
Surprise %-------------0.94%0.83%0.80%0.93%0.86%1.16%0.88%2.34%1.00%0.98%1.15%1.26%0.82%3.46%

According to undefined Wall Street analysts, Avidity Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RNA previous annual EPS of $NaN (undefined).

Avidity Biosciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.60$6.00900.00%Buy
BDTXBlack Diamond Therapeutics$2.99$14.75393.31%Buy
RLAYRelay Therapeutics$5.85$19.40231.62%Buy
PLRXPliant Therapeutics$14.49$39.71174.05%Buy
ARVNArvinas$26.80$71.82167.99%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
STOKStoke Therapeutics$13.10$30.60133.59%Buy
MLYSMineralys Therapeutics$13.50$30.00122.22%Buy
SWTXSpringWorks Therapeutics$30.94$67.33117.61%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
IGMSIGM Biosciences$15.69$20.3329.57%Buy
RNAAvidity Biosciences$44.82$54.5021.60%Buy
PTGXProtagonist Therapeutics$46.76$50.006.93%Buy
RVMDRevolution Medicines, Inc. Warrant$55.87$58.574.83%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

RNA Forecast FAQ


Yes, according to 8 Wall Street analysts, Avidity Biosciences (RNA) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of RNA's total ratings.

Avidity Biosciences (RNA) average price target is $54.5 with a range of $50 to $59, implying a 21.60% from its last price of $44.82. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for RNA stock, the company can go up by 21.60% (from the last price of $44.82 to the average price target of $54.5), up by 31.64% based on the highest stock price target, and up by 11.56% based on the lowest stock price target.

RNA's average twelve months analyst stock price target of $54.5 does not support the claim that Avidity Biosciences can reach $70 in the near future.

Avidity Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $15.13M (high $15.13M, low $15.13M), average EBITDA is $-15.129M (high $-15.129M, low $-15.129M), average net income is $-325M (high $-325M, low $-325M), average SG&A $50.03M (high $50.03M, low $50.03M), and average EPS is $-3.038 (high $-3.038, low $-3.038). RNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $15.53M (high $15.53M, low $15.53M), average EBITDA is $-15.53M (high $-15.53M, low $-15.53M), average net income is $-453M (high $-453M, low $-453M), average SG&A $51.36M (high $51.36M, low $51.36M), and average EPS is $-4.239 (high $-4.239, low $-4.239).

Based on Avidity Biosciences's last annual report (Dec 2023), the company's revenue was $9.56M, which missed the average analysts forecast of $18.61M by -48.64%. Apple's EBITDA was $-236M, beating the average prediction of $-18.614M by 1165.69%. The company's net income was $-212M, missing the average estimation of $-326M by -34.87%. Apple's SG&A was $54.19M, missing the average forecast of $61.56M by -11.97%. Lastly, the company's EPS was $-2.91, missing the average prediction of $-3.048 by -4.51%. In terms of the last quarterly report (Sep 2023), Avidity Biosciences's revenue was $2.82M, beating the average analysts' forecast of $2.21M by 27.30%. The company's EBITDA was $-58.059M, beating the average prediction of $-2.214M by 2522.83%. Avidity Biosciences's net income was $-52.358M, missing the average estimation of $-80.909M by -35.29%. The company's SG&A was $13.73M, beating the average forecast of $7.32M by 87.53%. Lastly, the company's EPS was $-0.71, missing the average prediction of $-0.757 by -6.17%